{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:28:16Z","timestamp":1793910496974,"version":"4.8.0"},"reference-count":123,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>One of the greatest burdens on the healthcare systems of modern civilization is cardiovascular diseases (CVDs). Therefore, the medical community is looking for ways to reduce the incidence of CVDs. Simple lifestyle changes from an unhealthy to a healthy lifestyle are the cornerstone of prevention, but other risk factors for cardiovascular disease are also being currently targeted, most notably dyslipidaemia. It is well known that lowering serum lipid levels, and in particular lowering elevated LDL-cholesterol, leads to a reduction in major cardiovascular events. Although the focus to date has been on LDL-cholesterol levels and lowering them with statin therapy, this is often not enough because of increased concentrations of other lipoprotein particles in the serum and residual cardiovascular risk. Since lowering LDL-cholesterol levels is successful in most cases, there has been a recent focus on lowering residual cardiovascular risk. In recent years, new therapeutic options have emerged that target triglyceride-rich lipoproteins, lipoprotein (a) and apolipoproteins C and B. The effects of these drugs on serious adverse cardiovascular events are not yet known, but recent studies with some of these drugs have shown significant results in lowering total lipid levels. The aim of this review is to present the current therapeutic options for the treatment of dyslipidaemia and to describe the newly approved drugs as well as the drugs that are still in development. Although at this stage we cannot say with certainty whether these agents will be approved and widely used, it is safe to say that our views on the treatment of dyslipidaemia are certainly changing.<\/jats:p>","DOI":"10.3390\/jcm12185839","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T07:57:17Z","timestamp":1694159837000},"page":"5839","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Present and Future of Dyslipidaemia Treatment\u2014A Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2824-9222","authenticated-orcid":false,"given":"Iveta","family":"Mer\u0107ep","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"},{"name":"Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andro","family":"Vujevi\u0107","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3977-9712","authenticated-orcid":false,"given":"Dominik","family":"Striki\u0107","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Radman","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sestre Milosrdnice University Hospital Centre, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Pe\u0107in","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017deljko","family":"Reiner","sequence":"additional","affiliation":[{"name":"Division of Metabolic Diseases, Department of Internal Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"},{"name":"Department of Cardiology and Congenital Diseases of Adults, Polish Mother\u2019s Memorial Hospital Research Institute, 93-338 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"ref_1","unstructured":"(2022, October 02). Cardiovascular Diseases. Available online: https:\/\/www.who.int\/health-topics\/cardiovascular-diseases."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.cjca.2021.02.009","article-title":"Cardiovascular Risk Factors and Prevention: A Perspective from Developing Countries","volume":"37","author":"Teo","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41569-021-00541-4","article-title":"Global epidemiology of dyslipidaemias","volume":"18","author":"Pirillo","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_4","first-page":"e38","article-title":"Heart Disease and Stroke Statistics\u20142016 Update: A Report From the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Finger, J.D., Busch, M.A., Du, Y., Heidemann, C., Knopf, H., Kuhnert, R., Lampert, T., Mensink, G.B.M., Neuhauser, H.K., and Rosario, A.S. (2022, October 02). Time Trends in Cardiometabolic Risk Factors in Adults. Dtsch \u00c4rztebl Int. 21 October 2016. Available online: https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2016.0712.","DOI":"10.3238\/arztebl.2016.0712"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart Disease and Stroke Statistics\u20142022 Update: A Report From the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"ref_7","unstructured":"\u010capkov\u00e1, N., Lustigov\u00e1, M., Krat\u011bnov\u00e1, J., and \u017dejglicov\u00e1, K. (2016). Zdravotn\u00ed Stav \u010cesk\u00e9 Populace: V\u00fdsledky Studie EHES 2014, St\u00e1tn\u00ed zdravotn\u00ed \u00fastav. [1st ed.]."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1210\/endrev\/bnab037","article-title":"A Modern Approach to Dyslipidemia","volume":"43","author":"Berberich","year":"2022","journal-title":"Endocr. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Mer\u0107ep, I., Striki\u0107, D., Sli\u0161kovi\u0107, A.M., and Reiner, \u017d. (2022). New Therapeutic Approaches in Treatment of Dyslipidaemia\u2014A Narrative Review. Pharmaceuticals, 15.","DOI":"10.3390\/ph15070839"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.35772\/ghm.2020.01078","article-title":"Secondary dyslipidemia: Its treatments and association with atherosclerosis","volume":"3","author":"Yanai","year":"2021","journal-title":"Glob. Health Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: The Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"ref_12","first-page":"18","article-title":"Lipoprotein(a): A risk factor for atherosclerosis and an emerging therapeutic target","volume":"109","author":"Arca","year":"2022","journal-title":"Heart"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_15","unstructured":"(2022, October 03). Statin Market Size, Share, Growth, Industry Analysis & Forecast 2022\u20132027. Available online: https:\/\/www.imarcgroup.com\/statin-market."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1194\/jlr.P002816","article-title":"Effect of statins on HDL-C: A complex process unrelated to changes in LDL-C: Analysis of the VOYAGER Database","volume":"51","author":"Barter","year":"2010","journal-title":"J. Lipid Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.numecd.2013.05.002","article-title":"Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update","volume":"23","author":"Reiner","year":"2013","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: A systematic review and meta-analysis","volume":"29","author":"Oorthuys","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamacardio.2021.3055","article-title":"Association of Statin Treatment with Progression of Coronary Atherosclerotic Plaque Composition","volume":"6","author":"Gianni","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"n1537","DOI":"10.1136\/bmj.n1537","article-title":"Associations between statins and adverse events in primary prevention of cardiovascular disease: Systematic review with pairwise, network, and dose-response meta-analyses","volume":"374","author":"Cai","year":"2021","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2174\/1381612820666141013134447","article-title":"Adverse effects of statins\u2014Myths and reality","volume":"21","author":"Reiner","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1016\/j.jacc.2021.04.075","article-title":"Effect of Statin Therapy on Cognitive Decline and Incident Dementia in Older Adults","volume":"77","author":"Zhou","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1001\/jamainternmed.2021.5714","article-title":"Association of Statin Therapy Initiation with Diabetes Progression: A Retrospective Matched-Cohort Study","volume":"181","author":"Mansi","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.amjcard.2015.05.011","article-title":"Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non\u2013High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry)","volume":"116","author":"Spinler","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s40292-019-00336-2","article-title":"Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy","volume":"26","author":"Perrone","year":"2019","journal-title":"High Blood Press. Cardiovasc. Prev. Off. J. Ital. Soc. Hypertens."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMoa2208275","article-title":"Polypill Strategy in Secondary Cardiovascular Prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bcp.12339","article-title":"Impact of statin adherence on cardiovascular disease and mortality outcomes: A systematic review: Impact of statin adherence","volume":"78","author":"Bhole","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4093\/dmj.2020.0001","article-title":"Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction","volume":"44","author":"Kim","year":"2020","journal-title":"Diabetes Metab. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0021-9150(89)90075-0","article-title":"Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration","volume":"77","author":"Malmendier","year":"1989","journal-title":"Atherosclerosis"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0021-9150(97)00313-4","article-title":"Regulation of apo A-I gene expression by fibrates","volume":"137","author":"Staels","year":"1998","journal-title":"Atherosclerosis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"19269","DOI":"10.1074\/jbc.270.33.19269","article-title":"Induction of the Acyl-Coenzyme A Synthetase Gene by Fibrates and Fatty Acids Is Mediated by a Peroxisome Proliferator Response Element in the C Promoter","volume":"270","author":"Schoonjans","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1161\/01.CIR.99.24.3125","article-title":"PPAR\u03b1 Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells","volume":"99","author":"Marx","year":"1999","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2174\/138161208783885362","article-title":"Fibrate-Associated Adverse Effects Beyond Muscle and Liver Toxicity","volume":"14","author":"Elisaf","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"ref_36","first-page":"CD009753","article-title":"Fibrates for primary prevention of cardiovascular disease events","volume":"2017","author":"Jakob","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12933-019-0864-7","article-title":"The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM\u03b1) paradigm: Conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation","volume":"18","author":"Fruchart","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1567-5688(15)30001-5","article-title":"A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate\u2013statin combination therapy","volume":"19","author":"Aguiar","year":"2015","journal-title":"Atheroscler. Suppl."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"904215","DOI":"10.3389\/fcvm.2022.904215","article-title":"Pemafibrate Prevents Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms","volume":"9","author":"Amioka","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","article-title":"Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force","volume":"325","author":"Averna","year":"2021","journal-title":"Atherosclerosis"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk","volume":"387","author":"Glynn","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"789931","DOI":"10.3389\/fcvm.2021.789931","article-title":"Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol","volume":"8","author":"Bardolia","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Vel\u00e1zquez, A.M., Bentanachs, R., Sala-Vila, A., L\u00e1zaro, I., Rodr\u00edguez-Morat\u00f3, J., S\u00e1nchez, R.M., Laguna, J.C., Roglans, N., and Alegret, M. (2022). KHK, PNPLA3 and PPAR as Novel Targets for the Anti-Steatotic Action of Bempedoic Acid. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071517"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and Safety of Bempedoic Acid in Patients with Hypercholesterolemia and Statin Intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e012352","DOI":"10.1161\/JAHA.119.012352","article-title":"CLEAR Serenity Trial: More Clarity for the Future of Bempedoic Acid in Patients Unable to Take Statins?","volume":"8","author":"Jia","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"108507","DOI":"10.1016\/j.pharmthera.2023.108507","article-title":"Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events","volume":"250","author":"Raschi","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"102003","DOI":"10.1016\/j.cpcardiol.2023.102003","article-title":"Clinical Efficacy and Safety of Bempedoic Acid in High Cardiovascular Risk Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"48","author":"Uddin","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"117182","DOI":"10.1016\/j.atherosclerosis.2023.06.973","article-title":"Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials","volume":"378","author":"Shapiro","year":"2023","journal-title":"Atherosclerosis"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12933-020-01101-9","article-title":"Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: A systematic review and meta-analysis","volume":"19","author":"Wang","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: A Review of its Metabolism, Pharmacokinetics and Drug Interactions","volume":"44","author":"Kosoglou","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2796.2008.02062.x","article-title":"Ezetimibe monotherapy for cholesterol lowering in 2722 people: Systematic review and meta-analysis of randomized controlled trials","volume":"265","author":"Pandor","year":"2009","journal-title":"J. Intern. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0195-668X(02)00803-5","article-title":"Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial","volume":"24","author":"Melani","year":"2003","journal-title":"Eur. Heart J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0002-9149(02)03236-8","article-title":"Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia","volume":"91","author":"Kerzner","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and Safety of Ezetimibe Coadministered with Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia","volume":"105","author":"Gaudet","year":"2002","journal-title":"Circulation"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e25114","DOI":"10.1097\/MD.0000000000025114","article-title":"Statin\/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation","volume":"100","author":"Oh","year":"2021","journal-title":"Medicine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5551\/jat.35626","article-title":"Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study","volume":"24","author":"Oikawa","year":"2017","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/CIRCULATIONAHA.117.029095","article-title":"Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients with Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"136","author":"Bohula","year":"2017","journal-title":"Circulation"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients with Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis","volume":"359","author":"Pedersen","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"9661752","DOI":"10.1155\/2021\/9661752","article-title":"The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"2021","author":"Jamialahmadi","year":"2021","journal-title":"Mediat. Inflamm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ajpath.2021.04.016","article-title":"Proprotein Convertase Subtilisin\/Kexin Type 9","volume":"191","author":"Macchi","year":"2021","journal-title":"Am. J. Pathol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev-med-042716-091351","article-title":"PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes","volume":"69","author":"Hess","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1536\/ihj.22-052","article-title":"Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome","volume":"63","author":"Hao","year":"2022","journal-title":"Int. Heart J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.4244\/EIJ-D-22-00269","article-title":"Evolocumab for prevention of microvascular dysfunction in patients undergoing percutaneous coronary intervention: The randomised, open-label EVOCATION trial","volume":"18","author":"Ishihara","year":"2022","journal-title":"EuroIntervention"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: A prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial","volume":"7","author":"Szarek","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/CIRCULATIONAHA.119.043826","article-title":"Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES","volume":"140","author":"Jukema","year":"2019","journal-title":"Circulation"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Basiak, M., Kosowski, M., Hachula, M., and Okopien, B. (2022). Impact of PCSK9 Inhibition on Proinflammatory Cytokines and Matrix Metalloproteinases Release in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque. Pharmaceuticals, 15.","DOI":"10.3390\/ph15070802"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Kosowski, M., Basiak, M., Hachu\u0142a, M., and Okopie\u0144, B. (2022). Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque. Medicina, 58.","DOI":"10.3390\/medicina58070969"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Huang, H.-C., Hsu, S.-J., Chang, C.-C., Chuang, C.-L., Hou, M.-C., and Lee, F.-Y. (2022). Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23137378"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"100483","DOI":"10.1016\/j.xkme.2022.100483","article-title":"Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)","volume":"4","author":"East","year":"2022","journal-title":"Kidney Med."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Parikh, R.R., Breve, F., Magnusson, P., Behzadi, P., and Pergolizzi, J. (2022, September 03). The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia. Cureus 3 June 2022. Available online: https:\/\/www.cureus.com\/articles\/92705-the-use-of-monoclonal-antibody-based-proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibitors-in-the-treatment-of-hypercholesterolemia.","DOI":"10.7759\/cureus.25641"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s40261-022-01173-3","article-title":"Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy","volume":"42","author":"Michaeli","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s11883-022-01056-0","article-title":"Inclisiran: How Widely and When Should We Use It?","volume":"24","author":"Pirillo","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"375","DOI":"10.31083\/j.rcm2311375","article-title":"Inclisiran: A New Pharmacological Approach for Hypercholesterolemia","volume":"23","author":"Maggioni","year":"2022","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: A patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14740338.2022.1988568","article-title":"Inclisiran: A small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia","volume":"21","author":"Banerjee","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jacl.2022.06.009","article-title":"Small interfering ribonucleic acid for cholesterol lowering\u2014Inclisiran","volume":"16","author":"Soffer","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"ref_89","first-page":"8129513","article-title":"Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9-A Narrative Review","volume":"2022","author":"Reiner","year":"2022","journal-title":"Cardiovasc. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12020-015-0838-9","article-title":"The role of ANGPTL3 in controlling lipoprotein metabolism","volume":"52","author":"Tikka","year":"2016","journal-title":"Endocrine"},{"key":"ref_91","first-page":"49","article-title":"Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia","volume":"14","author":"Kosmas","year":"2022","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for Homozygous Familial Hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1161\/ATVBAHA.120.315204","article-title":"ANGPTL3 Inhibition with Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia\u2014Brief Report","volume":"41","author":"Reeskamp","year":"2021","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of Vupanorsen on Non\u2013High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients with Elevated Cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12944-021-01589-4","article-title":"Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): Results of a proof-of-concept study","volume":"20","author":"Akinci","year":"2021","journal-title":"Lipids Health Dis."},{"key":"ref_98","unstructured":"Pfizer and Ionis Announce Discontinuation of Vupanorsen Clinical Development Program (2022, October 10). Pfizer. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-ionis-announce-discontinuation-vupanorsen."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) Reduction in Persons with Cardiovascular Disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_101","unstructured":"Inc IP (2022, October 11). Ionis Announces Enrollment Completion of Phase 3 Lp(a) HORIZON Cardiovascular Outcomes Study of Pelacarsen. Available online: https:\/\/www.prnewswire.com\/news-releases\/ionis-announces-enrollment-completion-of-phase-3-lpa-horizon-cardiovascular-outcomes-study-of-pelacarsen-301589746.html."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"A13951","DOI":"10.1161\/circ.142.suppl_3.13951","article-title":"Abstract 13951: Safety, Tolerability and Efficacy of Single-dose Amg 890, a Novel Sirna Targeting Lp(a), in Healthy Subjects and Subjects with Elevated Lp(a)","volume":"142","author":"Koren","year":"2020","journal-title":"Circulation"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals with Elevated Plasma Lipoprotein(a) Levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Gareri, C., Polimeni, A., Giordano, S., Tamm\u00e8, L., Curcio, A., and Indolfi, C. (2022). Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133884"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.4070\/kcj.2018.0343","article-title":"Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy","volume":"48","author":"Reiner","year":"2018","journal-title":"Korean Circ. J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e13841","DOI":"10.1111\/eci.13841","article-title":"Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials","volume":"52","author":"Calcaterra","year":"2022","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11883-020-00836-w","article-title":"Efficacy and Safety of Volanesorsen (ISIS 304801): The Evidence from Phase 2 and 3 Clinical Trials","volume":"22","author":"Fogacci","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/14779072.2018.1487290","article-title":"The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: The results of the ReFOCUS study","volume":"16","author":"Arca","year":"2018","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Alexander","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_111","unstructured":"Waylivra, E.M.A. (2022, October 13). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/waylivra."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jacl.2023.04.007","article-title":"APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia","volume":"17","author":"Prohaska","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacl.2022.06.005","article-title":"Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia","volume":"16","author":"Tardif","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40265-019-01114-z","article-title":"Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials","volume":"79","author":"Fogacci","year":"2019","journal-title":"Drugs"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","article-title":"Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: The pan-European retrospective observational study","volume":"29","author":"Steward","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41419-022-05039-6","article-title":"Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR","volume":"13","author":"Lee","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Mohamed, F., Mansfield, B., and Raal, F.J. (2023). Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol. J. Clin. Med., 12.","DOI":"10.3390\/jcm12155082"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40256-021-00497-3","article-title":"Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice","volume":"22","author":"Rossi","year":"2022","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: A meta-analysis","volume":"43","author":"Penson","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_123","unstructured":"(2022, October 18). The Top 300 of 2020. Available online: https:\/\/clincalc.com\/DrugStats\/Top300Drugs.aspx."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/18\/5839\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:47:14Z","timestamp":1760129234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/18\/5839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":123,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["jcm12185839"],"URL":"https:\/\/doi.org\/10.3390\/jcm12185839","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]}}}